Project Grant R13FD008427
Award Date
9/1/24
Completion Date
8/31/25
Dollars Obligated
$150K
Funding Federal Agency
Center for Biologics Evaluation and Research
Awarding Federal Agency
FDA Office of Acquisition and Grant Services
Federal Grant Program
93.103
Assistance Type
Project Grant
Place of Performance
Tucson, AZ 85718, USA
Similar Awards
This federal Cooperative Agreement award from the Food and Drug Administration (FDA) under CFDA program 93.103 (FDA Research) provides $249,984 to The Critical Path Institute (C-Path) to develop a Qualification Plan (QP) to support the qualification of the Virtual Reality Functional Capacity Assessment Tool-Short List (VRFCAT-SLX) as a performance outcome measure of cognition-dependent daily functioning for individuals with biomarker-positive, clinical stage 2 and 3 Alzheimer's disease. The...
This Cooperative Agreement award from the Food and Drug Administration (FDA) Research program (CFDA 93.103) provides $249,826 in funding to The Critical Path Institute (C-Path) to complete psychometric analyses and develop a quantitative study report to support the qualification of the Chronic Heart Failure Symptom Scale (CHF-SS) as a fit-for-purpose clinical outcome assessment for regulatory decision-making in heart failure drug development. The project involves three main aims: 1) finalizing...
This Cooperative Agreement award from the Food and Drug Administration (FDA) under the Food and Drug Administration Research program (CFDA 93.103) provides $150,000 in funding to the Pharmaceutical Inspection Co-Operation Scheme-Association De Droit Suisse to develop curricula and training tools for a web-based educational center called the PIC/S Inspectorates' Academy (PIA). The goal is to harmonize and standardize Good Manufacturing Practice (GMP) training and qualification processes for...
The U.S. Food and Drug Administration (FDA) awarded a $1.45M Cooperative Agreement under the FDA Research program (CFDA 93.103) to the Academy of Managed Care Pharmacy to conduct a study titled "Bridging the Gap: Using Foreign Real-World Data to Inform Interchangeable Biosimilar Approvals." The project aims to evaluate the feasibility and validity of using real-world data from the U.S., Italy, and Denmark to emulate a biosimilar interchangeability (switching) study. The results will be...
This Project Grant award from the Food and Drug Administration (FDA) Research program (CFDA 93.103) provides $400,000.00 to The Children's Hospital of Philadelphia (CHOP) to establish the PKDNET initiative. The goal of PKDNET is to create a robust data resource to identify a research-ready cohort of children with autosomal recessive polycystic kidney disease (ARPKD) and collect high-quality natural history data. This will help address key barriers to conducting clinical trials for ARPKD,...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $314,363 to Delineate Inc. to develop an innovative platform that uses large language models (LLMs) to accelerate the building and repurposing of quantitative systems pharmacology (QSP) models from scientific literature. The key objectives are to: (1) develop an LLM-powered platform for efficient QSP model construction...
The U.S. Food and Drug Administration (FDA) awarded a $741,663 Project Grant under the FDA Research program (CFDA 93.103) to the University of Pittsburgh to define the natural history of pediatric intestinal failure (IF). The grant will utilize the existing International Intestinal Failure Registry to collect high-quality longitudinal data on demographics, clinical characteristics, nutrition, genotype, and outcomes for children with both short bowel syndrome-related IF and functional IF. In...
The Department of Health and Human Services' Food and Drug Administration awarded The Johns Hopkins University a $3.2 million Project Grant under the FDA Research program (CFDA 93.103) for the period of September 15, 2022 through August 31, 2026. The grant aims to improve clinical trials for Ataxia Telangiectasia (A-T), a rare genetic disease, through three specific objectives: prospectively testing A-T severity stratification using genetic, phenotypic and laboratory markers; using RNA...
This federal Project Grant award, totaling $430,765.00, was provided by the National Center for Advancing Translational Sciences (NCATS) under the CFDA Program 93.350 to Duke University. The project aims to evaluate the efficacy of triacetin, an FDA-approved food additive, in treating propionic acidemia (PA), a rare metabolic disorder, by rebalancing the acetyl-CoA/propionyl-CoA ratio. Specifically, the two key objectives are: 1) to assess triacetin's ability to rectify metabolic abnormalities...
This Cooperative Agreement award from the Food and Drug Administration (FDA) under the FDA Research program (CFDA 93.103) provides $1,496,492.00 to the Sloan-Kettering Institute for Cancer Research to conduct research on elucidating tumor-specific cell surface proteomes in ultra-rare cancers like rhabdoid tumors and desmoplastic small round cell tumors. The goal is to gain a better understanding of these challenging, therapy-resistant cancers and identify potential new therapeutic targets. The...